All articles by GlobalData Healthcare

ECRD 2026: Europe’s rare disease bottleneck is funding rather than science

Rare disease R&D investment is outpacing the broader biotech market, while the pipeline of innovative therapies continues to deepen. With…
ECRD 2026: Navigating the rare disease diagnostic and drug development maze

The diagnostic odyssey describes the long journey that patients with rare diseases go through, starting from their first symptom up…
ADA26: Oral PCSK9 inhibitor enlicitide delivers robust LDL-C lowering

This year at the American Diabetes Association (ADA) Scientific Sessions, new Phase III data were presented evaluating the safety and…
ADA26: Early data for teplizumab demonstrates promise for slowing T1D progression

During the 2026 American Diabetes Association (ECO) Scientific Sessions in New Orleans, a real-world cohort of type 1 diabetic (T1D)…
ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowess

The American Society of Clinical Oncology (ASCO) 2026 Annual Meeting saw the presentation of several abstracts and presentations highlighting the…

ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC

Several abstracts and data presentations on emerging clinical research in non-small cell lung cancer prompted expert interest and discussion at…
ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

Kelonia Therapeutics presented results for the Phase I inMMyCAR clinical trial (NCT07075185) at the American Society of Clinical Oncology (ASCO)…
Emerging therapies for CNS tumours: key clinical trial updates to watch at ASCO 2026

At the 2026 American Society of Clinical Oncology (ASCO) annual congress, oral abstract presenters highlighted new and exciting central nervous…
ASCO 2026: Mixed SCLC result for Legend’s LB2102, Novartis expedites manufacture

Legend Biotech presented preliminary results from its ongoing Phase I/II trial of LB2102 (NCT05680922), an armoured delta-like ligand 3 (DLL3)-targeted…
ASCO26: Talzenna and Xtandi combo has first-line promise in HRR altered-mCSPC

At the 2026 American Society of Clinical Oncology (ASCO) annual congress, Pfizer presented top line data for the Phase III…